Anticonvulsant drugs in migraine prophylaxis
T H E R A P Y Migraine prophylaxis is still based on old drugs, and physicians facing this condition are always prompted to use any new possible choice. The most studied drug over last decade has been divalproex sodium, and many papers showed its efficacy in the treatment of episodic migraine, chronic migraine, transformed migraine, and related conditions. Valproate is well tolerated and many dosages have been used successfully. For the newer drugs, such as gabapentin, lamotrigine or topiramate, the evidence is less strong but rapidly increasing in the last 3-4 years. We review the principal characteristics of their use, according to dosages, duration of treatments, side effects, and significant efficacy. [3] presented his work at the "Headache 2000" congress, helded in London. In this open study, 40 patients were treated with a mean dosage of 550 mg/day for 2-6 months; 30 patients reported a reduction of almost 70% in the frequency of their migraine headaches, and headaches in the remaining migraines were about 40% less severe.
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In all of the clinical studies, whether open, retrospective or placebo-controlled and double-blind, divalproex sodium was an effective preventive treatment for migraine. Divalproex sodium has been studied as a prophylactic medication for migraine without aura [4] , migraine with and without aura [5] [6] [7] , transformed migraine [8, 9] refractory migraine [10, 11] , persistent migraine aura [12] , and pediatric migraine [13, 14] . The efficacy of divalproex sodium has been compared with that of propanolol [15] and flunarizine [16] .
Several reviews have summarized the clinical benefit of divalproex sodium in migraine [17] [18] [19] . Most patients received a dosage of 500-1000 mg, although the drug was also effective at low (400 mg/day) and high (2500 mg/day) dosages [7, 8, 20] . Before starting treatment, is useful obtain baseline laboratory data, including complete blood count and serum chemistry with liver enzymes. These should be repeated at two and six months, particularly in patients receiving polytherapy [17] . Recommended starting dose is 500 mg/day, with titration to 1000 mg/day in case of failure. Higher dosages are not indicated [19] . Divalproex sodium safety has been extensively studied and documented. Adverse events were usually mild or moderate in severity and transient. Nausea was the most common side effect, followed by alopecia, tremor, asthenia, dyspepsia, somnolence, and weight gain. In an open-label, long-term study, Silberstein et al. [21] noted that side effects were distinguishable in three groups: (a) nausea, vomiting, dizziness, and dyspesia were generally greatly reducted during treatment; (b) somnolence, asthenia, and diarrhea were reduced by approximately 50% or more; and (c) other adverse events, such as tremor and weight gain, remained relatively constant over time.
Recently, a new indication for divalproex sodium has been explored: as a drug for acute treatment of migraine crises [22] [23] [24] [25] . Intravenous sodium valproate (300-1000 mg) has good efficacy with minimal side effects: unusual taste sensation, somnolence, burning at injection site, nausea, and dizziness [25] . When compared with intravenous dihydroergotamine, the efficacy was similar but divalproex sodium caused significantly fewer adverse events.
Finally, divalproex sodium may be considered in the prophylaxis of migraine in children. A retrospective study found great clinical efficacy in children receiving a daily dosage of 15-45 mg divalproex sodium per kilogram body weight: 50% or more reduction in headache frequency was seen in 78.5% of patients after 4 months of treatment and 9.5% of the patients became pain free [13] . A second, openlabel study [14] testing a daily dosage of 250-1125 mg divalproex sodium (3.09-32.89 mg/kg body weight) also found great clinical efficacy: a 50% or greater reduction in headache frequency was seen in 60% of patients (the treatment duration was not indicated), and 15% of the patients became headache free. These studies strongly support the efficacy of divalproex sodium in young people but, unfortunately, the lack of controlled design makes these data not fully reliable.
Lamotrigine
The first report on the use of lamotrigine in migraine prophylaxis was published in 1997 [26] . To date, this is the only study regarding patients with both migraine with and without aura. In the study, 37 patients were randomized to placebo and 40 to treatment with lamotrigine. Active treatment either was started at the full dose of 200 mg/day (18 patients) or with a slow dose-escalation (19 patients) to avoid skin reaction. Improvement was greater on placebo and these changes, not statistically significant, indicated that lamotrigine is ineffective for migraine prophylaxis.
In 1999, Lampl et al.
[27] enrolled 15 patients with migraine with aura or aura without migraine and treated them for a period of 4 months, with a 3-month follow-up. Lamotrigine was slowly titrated up to 100 mg/day. Aura symptoms were significantly reduced from baseline to month 4. In all 15 cases, increases in aura frequency and duration were observed following cessation of treatment.
D'Andrea et al.
[28] studied 24 patients affected by migraine with aura with a high frequency of attacks. The patients underwent 3 months of therapy with lamotrigine at 100 mg/day. Of the 21 patients who completed the study, 13 were symptom-free at the third month of therapy. Only one patient was completely unresponsive to the drug.
In all 3 of the previously discussed studies, adverse events were mild or moderate, and were mainly skin rash, paresthesias, dizziness, and sleep disturbances.
Gabapentin
Gabapentin has only been recently employed in the treatment of migraine with or without aura. A double-blind, randomized, placebo-controlled study was carried on 63 patients (35 treatment, 28 placebo) at the dosage of 1200 S123 mg/day for 3 months [29] . Adverse events were mild and transient, and no patient withdrew because of side effects. Somnolence, dizziness, tremor, ataxia, and fatigue were the major compliants and occurred in 13 patients (27%). All 3 study groups (placebo, migraine with aura, migraine without aura) obtained significant improvement at the third month of therapy vs. baseline. No significant difference was observed between active treatment and placebo.
Mathew et al.
[30] treated 98 patients with gabapentin, administered in increasing dosages up to 2400 mg/day after 4 weeks. A significant response was observed in these patients compared to 45 who received placebo: there was a 50% reduction of migraine in 46.6% of treated and 16.1% of placebo patients. Adverse events were similar to those in the previous study, but led to withdrawal of 16.3% of treated patients and 8.9% of placebo patients.
Topiramate
After the report of the efficacy of topiramate in cluster headache patients [ 
Cochrane review
Published in 2000, the Cochrane review of "anticonvulsant drugs for acute and chronic pain" [41] considered only three placebo-controlled studies of migraine prophylaxis, during the period from January 1966 to February 1994. Two studies [2, 5] showed greater effect with the anticonvulsant than with placebo. The authors stated that "these studies showed anticonvulsants to be effective". 
